Table 24: Product Sales year-on-year analysis: Q2 2025 (Unreviewed) The Q2 2025 information in respect of the three months ended 30 June 2025 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | World | | US | | Emerging Markets | | Europe | | Established RoW | For the half year ended 30 June | | | | Change | | | | Change | | | | Change | | | | Change | | | | Change | | | $m | | Act % | | CER % | | $m | | Act % | | $m | | Act % | | CER % | | $m | | Act % | | CER % | | $m | | Act % | | CER % | Tagrisso | | 1,810 | | 13 | | 12 | | 761 | | 16 | | 489 | | 13 | | 15 | | 351 | | 8 | | 4 | | 209 | | 9 | | 5 | Imfinzi | | 1,455 | | 27 | | 26 | | 844 | | 36 | | 152 | | 31 | | 35 | | 285 | | 26 | | 21 | | 174 | | (5) | | (8) | Calquence | | 872 | | 10 | | 10 | | 583 | | 5 | | 49 | | 36 | | 43 | | 198 | | 19 | | 14 | | 42 | | 27 | | 28 | Lynparza | | 838 | | 13 | | 11 | | 378 | | 18 | | 162 | | 6 | | 7 | | 229 | | 11 | | 7 | | 69 | | 5 | | 2 | Enhertu | | 230 | | 81 | | 82 | | - | | - | | 156 | | n/m | | n/m | | 51 | | 63 | | 56 | | 23 | | 24 | | 28 | Zoladex | | 284 | | 4 | | 5 | | 4 | | (8) | | 219 | | 9 | | 11 | | 38 | | (9) | | (13) | | 23 | | (9) | | (11) | Truqap | | 170 | | 84 | | 84 | | 142 | | 57 | | 6 | | n/m | | n/m | | 14 | | n/m | | n/m | | 8 | | n/m | | n/m | Imjudo | | 89 | | 20 | | 18 | | 57 | | 17 | | 7 | | 93 | | 84 | | 12 | | 39 | | 35 | | 13 | | - | | (4) | Other Oncology | | 106 | | (12) | | (13) | | 1 | | (76) | | 70 | | (11) | | (10) | | 5 | | (27) | | (30) | | 30 | | - | | (5) | Oncology | | 5,854 | | 18 | | 17 | | 2,770 | | 20 | | 1,310 | | 19 | | 22 | | 1,183 | | 17 | | 12 | | 591 | | 5 | | 2 | Farxiga | | 2,150 | | 11 | | 10 | | 420 | | 6 | | 859 | | 13 | | 15 | | 765 | | 13 | | 8 | | 106 | | 3 | | (1) | Crestor | | 319 | | 9 | | 9 | | 12 | | 3 | | 275 | | 17 | | 18 | | - | | n/m | | n/m | | 32 | | (10) | | (13) | Brilinta | | 215 | | (37) | | (38) | | 99 | | (48) | | 63 | | (20) | | (20) | | 51 | | (26) | | (29) | | 2 | | (46) | | (39) | Seloken | | 148 | | (2) | | 1 | | - | | n/m | | 143 | | (2) | | - | | 4 | | 4 | | 11 | | 1 | | (5) | | (3) | Lokelma | | 175 | | 29 | | 27 | | 75 | | 18 | | 33 | | 52 | | 54 | | 30 | | 33 | | 29 | | 37 | | 30 | | 24 | roxadustat | | 72 | | (18) | | (18) | | - | | - | | 72 | | (18) | | (18) | | - | | - | | - | | - | | - | | - | Wainua | | 44 | | n/m | | n/m | | 43 | | n/m | | - | | - | | - | | 1 | | - | | - | | - | | - | | - | Other CVRM | | 138 | | (27) | | (28) | | 16 | | (73) | | 67 | | 24 | | 24 | | 38 | | (35) | | (37) | | 17 | | (8) | | (12) | CVRM | | 3,261 | | 3 | | 3 | | 665 | | (10) | | 1,512 | | 9 | | 11 | | 889 | | 5 | | 1 | | 195 | | 2 | | (2) | Symbicort | | 715 | | (1) | | (1) | | 319 | | 7 | | 168 | | (15) | | (14) | | 137 | | (5) | | (8) | | 91 | | 11 | | 11 | Fasenra | | 502 | | 19 | | 18 | | 307 | | 14 | | 26 | | 33 | | 36 | | 125 | | 27 | | 22 | | 44 | | 20 | | 18 | Breztri | | 283 | | 21 | | 20 | | 147 | | 22 | | 65 | | 7 | | 8 | | 46 | | 32 | | 27 | | 25 | | 30 | | 28 | Tezspire | | 112 | | 97 | | 91 | | - | | - | | 9 | | n/m | | n/m | | 72 | | n/m | | n/m | | 31 | | 60 | | 55 | Pulmicort | | 106 | | (32) | | (32) | | 1 | | (58) | | 81 | | (35) | | (36) | | 15 | | (14) | | (18) | | 9 | | 2 | | 2 | Saphnelo | | 167 | | 49 | | 48 | | 145 | | 44 | | 4 | | n/m | | n/m | | 12 | | n/m | | n/m | | 6 | | 41 | | 31 | Airsupra | | 42 | | n/m | | n/m | | 42 | | n/m | | - | | n/m | | n/m | | - | | - | | - | | - | | - | | - | Other R&I | | 61 | | (23) | | (24) | | 16 | | (35) | | 28 | | (25) | | (25) | | 15 | | 2 | | (3) | | 2 | | (8) | | (7) | R&I | | 1,988 | | 11 | | 10 | | 977 | | 18 | | 381 | | (14) | | (13) | | 422 | | 21 | | 16 | | 208 | | 20 | | 19 | Beyfortus | | 98 | | n/m | | n/m | | 73 | | n/m | | - | | - | | - | | 24 | | n/m | | n/m | | 1 | | 34 | | 27 | Synagis | | 49 | | (39) | | (37) | | - | | n/m | | 38 | | (7) | | (1) | | - | | n/m | | n/m | | 11 | | (68) | | (69) | FluMist | | 10 | | n/m | | n/m | | - | | n/m | | - | | - | | - | | - | | n/m | | n/m | | 10 | | - | | - | Other V&I | | - | | n/m | | n/m | | - | | - | | - | | - | | - | | - | | n/m | | n/m | | - | | n/m | | n/m | V&I | | 157 | | 40 | | 42 | | 73 | | n/m | | 38 | | (6) | | (1) | | 24 | | n/m | | n/m | | 22 | | (39) | | (40) | Ultomiris | | 1,177 | | 25 | | 23 | | 667 | | 21 | | 61 | | 76 | | 86 | | 270 | | 29 | | 24 | | 179 | | 18 | | 12 | Soliris | | 530 | | (24) | | (22) | | 280 | | (30) | | 159 | | 23 | | 38 | | 56 | | (52) | | (54) | | 35 | | (37) | | (38) | Strensiq | | 395 | | 16 | | 15 | | 319 | | 12 | | 16 | | 65 | | 58 | | 31 | | 30 | | 26 | | 29 | | 27 | | 21 | Koselugo | | 137 | | 20 | | 18 | | 52 | | (5) | | 36 | | 51 | | 50 | | 37 | | 42 | | 37 | | 12 | | 28 | | 22 | Other Rare Disease | | 55 | | 16 | | 14 | | 28 | | 13 | | 6 | | 7 | | 4 | | 18 | | 20 | | 16 | | 3 | | 37 | | 32 | Rare Disease | | 2,294 | | 7 | | 7 | | 1,346 | | 3 | | 278 | | 37 | | 48 | | 412 | | 5 | | 1 | | 258 | | 7 | | 2 | Nexium | | 198 | | (10) | | (9) | | 18 | | (30) | | 157 | | 7 | | 9 | | 6 | | (49) | | (55) | | 17 | | (52) | | (51) | Other | | 43 | | (10) | | (11) | | 3 | | 12 | | 29 | | (12) | | (11) | | 10 | | (12) | | (18) | | 1 | | 4 | | (3) | Other Medicines | | 241 | | (10) | | (9) | | 21 | | (26) | | 186 | | 4 | | 5 | | 16 | | (32) | | (38) | | 18 | | (50) | | (50) | Total Medicines | | 13,795 | | 11 | | 10 | | 5,852 | | 12 | | 3,705 | | 11 | | 13 | | 2,946 | | 12 | | 8 | | 1,292 | | 4 | | 1 |
The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth.
|